1.32

11.41% -0.17

After Hours: 1.33 0.01 +0.76%

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.32, with a volume of 3.06M. It is down -11.41% in the last 24 hours and down -23.70% over the past month. Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Previous Close:

$1.49

Open:

$1.49

24h Volume:

3.06M

Relative Volume:

2.09

Market Cap:

$95.68M

Revenue:

Net Income/Loss:

$-44.95M

P/E Ratio:

-1.479

EPS:

-0.8925

Net Cash Flow:

$-56.37M

1W Performance:

-27.87%

1M Performance:

-23.70%

6M Performance:

+8.20%

1Y Performance:

-35.61%

1-Day Range:

$1.303

$1.49

1-Week Range:

$1.303

$1.85

52-Week Range:

$0.8719

$2.99

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.32	95.68M	0	-44.95M	-56.37M	-0.8925
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

08:27 AM

Form 424B5 Biomea Fusion Inc For: 27 September By Investing.com - Investing.com Nigeria

08:27 AM

Sep 26, 2026

Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA) - Seeking Alpha

Sep 24, 2026

Sep 23, 2026

Biomea Fusion Scraps Stock Offering, Sending Shares Down 19% After Hours - finance.biggo.com

Sep 23, 2026

Biomea Fusion Shares Fall After Terminating Proposed Public Offering - marketscreener.com

Sep 23, 2026

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - benzinga.com

Sep 23, 2026

Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next - TipRanks

Sep 23, 2026

Biomea stock slips after delaying trial readout (BMEA:NASDAQ) - Seeking Alpha

Sep 23, 2026

Biomea Fusion stock ticks up after canceling public offering By Investing.com - Investing.com Nigeria

Sep 23, 2026

Biomea Fusion stock ticks up after canceling public offering - Investing.com

Sep 23, 2026

Biomea Fusion terminates proposed public offering By Investing.com - Investing.com Canada

Sep 23, 2026

Biomea Fusion terminates proposed public offering - Investing.com

Sep 23, 2026

Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities - TradingView

Sep 23, 2026

Biomea Fusion Announces Termination of Proposed Public Offering of Securities - globenewswire.com

Sep 23, 2026

Biomea Fusion stock tumbles on public offering launch - Investing.com

Sep 23, 2026

Sep 22, 2026

Biomea Fusion stock tumbles on public offering launch By Investing.com - Investing.com Nigeria

Sep 22, 2026

Biomea Fusion Updates Timeline for BMF-650 Phase I Data - TipRanks

Sep 22, 2026

Biomea Fusion announces public offering of common stock - Investing.com

Sep 22, 2026

Biomea Fusion announces public offering of common stock By Investing.com - Investing.com Nigeria

Sep 22, 2026

Biomea Fusion Proposes Public Offering of Common Stock, Pre-Funded Warrants - marketscreener.com

Sep 22, 2026

Biomea Fusion Announces Proposed Public Offering of Securities - The Manila Times

Sep 22, 2026

Biomea Fusion announces proposed public offering of shares - TradingView

Sep 22, 2026

No size or terms are set for Biomea Fusion's share offering. Its underwriter may buy up to 15% more. - Stock Titan

Sep 22, 2026

BMEA Stock Price and Chart — NASDAQ:BMEA - TradingView

Sep 22, 2026

Sep 20, 2026

Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 17, 2026

Biomea Fusion Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock GainRevenue Recognition Risk - dars.gov.et

Sep 17, 2026

Sep 16, 2026